Actively Recruiting
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
Led by Hansoh BioMedical R&D Company · Updated on 2024-10-09
84
Participants Needed
1
Research Sites
83 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The purpose of this first in human study is to evaluate the safety, tolerability, pharmacokinetics (PK),and pharmacodynamics (PD) of HS-10390 in healthy subjects.
CONDITIONS
Official Title
A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy male or female subjects between the ages of 18-45 years
- Have no reproductive potential; or agree to use a highly effective method of contraception and refrain from donating sperm or eggs during the study period and for at least 6 months after last dosing
- Have signed the informed consent form approved by the IRB
You will not qualify if you...
- History or evidence of significant cardiovascular, pulmonary, endocrine, gastrointestinal, psychiatric, neurologic, hematological, or metabolic diseases that interfere with drug absorption, metabolism, or excretion
- Current or recent (past 30 days) clinically significant infection, history of active tuberculosis, or positive screening for infectious diseases including tuberculosis, viral hepatitis, AIDS, or syphilis
- History of or current allergic disease
- History of drug or alcohol abuse or positive test results for alcohol or drugs of abuse
- Smoking 5 or more cigarettes per day within past 3 months or positive test for nicotine
- Clinically significant abnormal physical exam, vital signs, lab values, ECGs, or imaging tests
- Pregnant or breastfeeding female subjects
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Zhongda Hospital, Affiliated to Southeast University
Nanjing, Jiangsu, China
Actively Recruiting
Research Team
B
Bicheng Liu
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
DOUBLE
Allocation
RANDOMIZED
Model
SEQUENTIAL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here